Vyndaqel (Tafamidis) – Treatment for Transthyretin Familial Amyloid Polyneuropathy

3l-image-Vyndaqel
Vyndaqel is approved by the European Commission and also awarded orphan drug designation in the US. Image courtesy of Pfizer.